{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:57:34Z","timestamp":1792598254622,"version":"4.5.0"},"reference-count":104,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":189,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873444"],"award-info":[{"award-number":["81873444"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070213"],"award-info":[{"award-number":["82070213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370196"],"award-info":[{"award-number":["82370196"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acute myeloid leukemia (AML) is a clonal malignant disease that arises from hematopoietic stem cells and is characterized by high genetic heterogeneity. AML has a poor prognosis, with a low 5-year survival rate, and is typically treated with chemotherapy. The management of AML, particularly for cases that are relapsed or refractory to conventional chemotherapy and transplantation, remains a formidable clinical challenge. This comprehensive review systematically evaluates the current landscape of cellular immunotherapeutic strategies for AML. We focus on the mechanisms of action, recent clinical progress, and persistent challenges associated with a range of adoptive cell therapies. These include natural killer cell-based infusions, and engineered approaches such as chimeric antigen receptor-T, CAR-NK, and CAR-macrophage therapies. Furthermore, we examine the roles of tumor-infiltrating lymphocytes and cytokine-induced killer cells. Our analysis synthesizes evidence from preclinical studies and clinical trials to assess the potential of these modalities in inducing durable antileukemic responses. We conclude that while cellular immunotherapies represent a transformative frontier in AML treatment, their broad application is currently constrained by target antigen heterogeneity, a complex tumor microenvironment, and significant toxicities. Finally, this review discusses strategic innovations necessary to overcome these barriers, highlighting directions for future research aimed at enhancing the efficacy and safety of these promising treatments for AML patients.<\/jats:p>","DOI":"10.1093\/immadv\/ltag012","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T11:41:38Z","timestamp":1783424498000},"source":"Crossref","is-referenced-by-count":0,"title":["Cellular immunotherapy for acute myeloid leukemia: from bench to bedside"],"prefix":"10.1093","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1061-3938","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei \u00a0","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei \u00a0","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobing","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital , Chengdu, Sichuan \u00a0","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology , Wuhan, Hubei \u00a0","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026102111365770000_ltag012-B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1182\/blood.2023022481","article-title":"How I treat refractory and relapsed acute myeloid leukemia","volume":"143","author":"Thol","year":"2024","journal-title":"Blood"},{"key":"2026102111365770000_ltag012-B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"2026102111365770000_ltag012-B3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3760\/cma.j.issn.0253-2727.2021.12.006","article-title":"[Analysis of risk factors of relapse after allogeneic hematopoietic stem cell transplantation in patients with t (8;21) acute myeloid leukemia]","volume":"42","author":"Guo","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2026102111365770000_ltag012-B4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3760\/cma.j.issn.0253-2727.2022.07.016","article-title":"[Advances in the recognition of acute myeloid leukemia with RARG-rearrangement]","volume":"43","author":"Shi","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2026102111365770000_ltag012-B5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3727\/096504020X15965357399750","article-title":"Outcomes of patients with acute myeloid leukemia who relapse after 5 years of complete remission","volume":"28","author":"Patel","year":"2021","journal-title":"Oncol Res"},{"key":"2026102111365770000_ltag012-B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1734327","article-title":"Defining the role of natural killer cells in acute myeloid leukemia through the lens of single-cell omics","volume":"17","author":"Liang","year":"2026","journal-title":"Front Immunol"},{"key":"2026102111365770000_ltag012-B7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1182\/bloodadvances.2019001053","article-title":"KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation","volume":"4","author":"Weisdorf","year":"2020","journal-title":"Blood Adv"},{"key":"2026102111365770000_ltag012-B8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/biomedicines13040857","article-title":"The role of NK cells in cancer immunotherapy: mechanisms, evasion strategies, and therapeutic advances","volume":"13","author":"Morcillo-Martin-Romo","year":"2025","journal-title":"Biomedicines"},{"key":"2026102111365770000_ltag012-B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04113-x","article-title":"Recent advances of cell therapies for AML\/MDS: exploring the therapeutic potential of innate immune cells in AML\/MDS","author":"Chang","year":"21, 2025","journal-title":"Int J Hematol"},{"key":"2026102111365770000_ltag012-B10","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2601404","article-title":"Synergistic immune interactions between T cells and natural killer cells in allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: current status and future directions","volume":"58","author":"Wang","year":"2026","journal-title":"Ann Med"},{"key":"2026102111365770000_ltag012-B11","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026102111365770000_ltag012-B12","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"2026102111365770000_ltag012-B13","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"key":"2026102111365770000_ltag012-B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154334","article-title":"Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse","volume":"132","author":"Shapiro","year":"2022","journal-title":"J Clin Invest"},{"key":"2026102111365770000_ltag012-B15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-025-01669-3","article-title":"First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer","volume":"18","author":"Shapiro","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026102111365770000_ltag012-B16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41392-024-02065-y","article-title":"A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026102111365770000_ltag012-B17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13287-024-03869-z","article-title":"Cytokine-induced killer cells: new insights for therapy of hematologic malignancies","volume":"15","author":"Ghanbari Sevari","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"2026102111365770000_ltag012-B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00262-023-03605-1","article-title":"Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy","volume":"73","author":"Sharma","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026102111365770000_ltag012-B19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jcyt.2014.09.006","article-title":"Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood","volume":"17","author":"Zhang","year":"2015","journal-title":"Cytotherapy"},{"key":"2026102111365770000_ltag012-B20","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.bbmt.2019.03.004","article-title":"Clearance of hematologic malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions","volume":"25","author":"Merker","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026102111365770000_ltag012-B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1240330","article-title":"Case report: dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer","volume":"10","author":"Mehling","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026102111365770000_ltag012-B22","doi-asserted-by":"publisher","first-page":"9291","DOI":"10.1002\/jcp.29827","article-title":"Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy","volume":"235","author":"Zhang","year":"2020","journal-title":"J Cell Physiol"},{"key":"2026102111365770000_ltag012-B23","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.2147\/CMAR.S199817","article-title":"Assessment of the presence and anti-tumor potential of tumor-infiltrating lymphocytes in patients with acute myeloid leukemia","volume":"11","author":"Wei","year":"2019","journal-title":"Cancer Manag Res"},{"key":"2026102111365770000_ltag012-B24","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.imbio.2019.05.001","article-title":"Tumor infiltrating lymphocytes from acute myeloid leukemia marrow can be reverted to CD45RA+ central memory state by reactivation in SIP (simulated infective protocol)","volume":"224","author":"Teo","year":"2019","journal-title":"Immunobiology"},{"key":"2026102111365770000_ltag012-B25","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000270","article-title":"The tumor microenvironment in hematologic malignancies: immune evasion, metabolic reprogramming, and therapeutic resistance","volume":"8","author":"Walid","year":"2026","journal-title":"Blood sci"},{"key":"2026102111365770000_ltag012-B26","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"2026102111365770000_ltag012-B27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1464218","article-title":"CAR-macrophage: breaking new ground in cellular immunotherapy","volume":"12","author":"Huang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"2026102111365770000_ltag012-B28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026102111365770000_ltag012-B29","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","article-title":"IMGN779, a novel CD33-targeting antibody-drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML","volume":"17","author":"Kovtun","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026102111365770000_ltag012-B30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/sj.leu.2401743","article-title":"Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias","volume":"14","author":"Frankel","year":"2000","journal-title":"Leukemia"},{"key":"2026102111365770000_ltag012-B31","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/ijms24032718","article-title":"CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm","volume":"24","author":"Pelosi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026102111365770000_ltag012-B32","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1182\/blood-2007-03-083048","article-title":"The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells","volume":"110","author":"van Rhenen","year":"2007","journal-title":"Blood"},{"key":"2026102111365770000_ltag012-B33","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/ajt.14020","article-title":"The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review","volume":"17","author":"AlDabbagh","year":"2017","journal-title":"Am J Transplant"},{"key":"2026102111365770000_ltag012-B34","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","article-title":"CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia","volume":"104","author":"Naik","year":"2019","journal-title":"Haematologica"},{"key":"2026102111365770000_ltag012-B35","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"2026102111365770000_ltag012-B36","doi-asserted-by":"publisher","first-page":"455","DOI":"10.12182\/20230560101","article-title":"[Latest findings on the role of CD47 in tumor immune evasion and related targeted therapies]","volume":"54","author":"Jie","year":"2023","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"2026102111365770000_ltag012-B37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.humpath.2012.07.007","article-title":"Preferential up-regulation of osteopontin in primary central nervous system lymphoma does not correlate with putative receptor CD44v6 or CD44H expression","volume":"44","author":"Yuan","year":"2013","journal-title":"Hum Pathol"},{"key":"2026102111365770000_ltag012-B38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1376554","article-title":"Chimeric antigen receptor (CAR) modified T cells in acute myeloid leukemia: limitations and expectations","volume":"12","author":"Guijarro-Albaladejo","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"2026102111365770000_ltag012-B39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s13346-018-0589-2","article-title":"The folate receptor beta as a macrophage-mediated imaging and therapeutic target in rheumatoid arthritis","volume":"9","author":"Chandrupatla","year":"2019","journal-title":"Drug Deliv Transl Res"},{"key":"2026102111365770000_ltag012-B40","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2362.2007.01746.x","article-title":"Expression of the target receptor CD33 in CD34+\/CD38-\/CD123+ AML stem cells","volume":"37","author":"Hauswirth","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"2026102111365770000_ltag012-B41","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3324\/haematol.2011.043786","article-title":"High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation","volume":"96","author":"De Propris","year":"2011","journal-title":"Haematologica"},{"key":"2026102111365770000_ltag012-B42","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"2026102111365770000_ltag012-B43","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ijc.33865","article-title":"CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"150","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"2026102111365770000_ltag012-B44","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s12185-024-03809-w","article-title":"CAR-T cell therapy in AML: recent progress and future perspectives","volume":"120","author":"Saito","year":"2024","journal-title":"Int J Hematol"},{"key":"2026102111365770000_ltag012-B45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"2026102111365770000_ltag012-B46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2174\/1871529X19666190627100613","article-title":"CD123: a novel biomarker for diagnosis and treatment of leukemia","volume":"19","author":"Shi","year":"2019","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"2026102111365770000_ltag012-B47","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"2026102111365770000_ltag012-B48","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3389\/fonc.2019.01358","article-title":"Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+ AML","volume":"9","author":"Yao","year":"2019","journal-title":"Front Oncol"},{"key":"2026102111365770000_ltag012-B49","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"2026102111365770000_ltag012-B50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1945804","article-title":"Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML","volume":"10","author":"Meyer","year":"2021","journal-title":"Oncoimmunology"},{"key":"2026102111365770000_ltag012-B51","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.ymthe.2025.03.052","article-title":"CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes","volume":"33","author":"Khalifeh","year":"2025","journal-title":"Mol Ther"},{"key":"2026102111365770000_ltag012-B52","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"key":"2026102111365770000_ltag012-B53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","article-title":"Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia","volume":"34","author":"Morsink","year":"2019","journal-title":"Blood Rev"},{"key":"2026102111365770000_ltag012-B54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","article-title":"Targeting CLL-1 for acute myeloid leukemia therapy","volume":"12","author":"Ma","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2026102111365770000_ltag012-B55","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.3390\/ijms18112259","article-title":"Development of A chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia","volume":"18","author":"Laborda","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2026102111365770000_ltag012-B56","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1016\/j.ymthe.2017.05.024","article-title":"Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1","volume":"25","author":"Tashiro","year":"2017","journal-title":"Mol Ther"},{"key":"2026102111365770000_ltag012-B57","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026102111365770000_ltag012-B58","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12967-024-05705-7","article-title":"Efficacy and safety of CAR-T therapy targeting CLL1 in patients with extramedullary diseases of acute myeloid leukemia","volume":"22","author":"Zhao","year":"2024","journal-title":"J Transl Med"},{"key":"2026102111365770000_ltag012-B59","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1073\/pnas.88.2.603","article-title":"Isolation and characterization of the genomic human CD7 gene: structural similarity with the murine thy-1 gene","volume":"88","author":"Schanberg","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026102111365770000_ltag012-B60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40164-022-00318-6","article-title":"CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed\/refractory acute myeloid leukemia","volume":"11","author":"Cao","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"2026102111365770000_ltag012-B61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0145-2126(03)00180-2","article-title":"Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia","volume":"28","author":"Chang","year":"2004","journal-title":"Leuk Res"},{"key":"2026102111365770000_ltag012-B62","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70151","article-title":"Stable expressed DNMT3A mutants predict a poor prognosis in acute myeloid leukemia patients without receiving hematopoietic stem cell transplantation","volume":"6","author":"Zhang","year":"2025","journal-title":"MedComm (2020)"},{"key":"2026102111365770000_ltag012-B63","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13148-018-0476-1","article-title":"Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome","volume":"10","author":"Lin","year":"2018","journal-title":"Clin Epigenetics"},{"key":"2026102111365770000_ltag012-B64","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1342998","article-title":"CD7-positive leukemic blasts with DNMT3A mutations predict poor prognosis in patients with acute myeloid leukemia","volume":"14","author":"Bai","year":"2024","journal-title":"Front Oncol"},{"key":"2026102111365770000_ltag012-B65","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"2026102111365770000_ltag012-B66","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12967-022-03797-7","article-title":"Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R\/R-AML)","volume":"20","author":"Lu","year":"2022","journal-title":"J Transl Med"},{"key":"2026102111365770000_ltag012-B67","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"key":"2026102111365770000_ltag012-B68","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"2026102111365770000_ltag012-B69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl Microbiol Biotechnol"},{"key":"2026102111365770000_ltag012-B70","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","article-title":"Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis","volume":"390","author":"Hu","year":"2024","journal-title":"N Engl J Med"},{"key":"2026102111365770000_ltag012-B71","first-page":"403","article-title":"CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's lymphomas","volume":"6","author":"Onea","year":"2016","journal-title":"Am J Cancer Res"},{"key":"2026102111365770000_ltag012-B72","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cll.2021.03.012","article-title":"Hematopathologic correlates of CAR T-cell therapy","volume":"41","author":"Dolan","year":"2021","journal-title":"Clin Lab Med"},{"key":"2026102111365770000_ltag012-B73","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.lrr.2018.03.002","article-title":"Anti-CD19 chimeric antigen receptor targeting of CD19 + acute myeloid leukemia","volume":"9","author":"Ma","year":"2018","journal-title":"Leuk Res Rep"},{"key":"2026102111365770000_ltag012-B74","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1097\/HS9.0000000000000937","article-title":"CAR-T in the treatment of acute myeloid leukemia: barriers and how to overcome them","volume":"7","author":"Vanhooren","year":"2023","journal-title":"Hemasphere"},{"key":"2026102111365770000_ltag012-B75","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/biomedicines12061194","article-title":"CAR-T Cells in acute myeloid leukemia: where do we stand?","volume":"12","author":"Damiani","year":"2024","journal-title":"Biomedicines"},{"key":"2026102111365770000_ltag012-B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2024.103471","article-title":"Point of care CD19 chimeric antigen receptor (CAR) T-cells for relapsed\/refractory acute myeloid leukemia (AML) with aberrant CD19 antigen expression","volume":"72","author":"Danylesko","year":"2024","journal-title":"Curr Res Transl Med"},{"key":"2026102111365770000_ltag012-B77","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-025-01708-z","article-title":"CD19 CAR-T in relapsed t(8;21) AML: a single-center prospective phase II clinical trial","volume":"18","author":"Yin","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026102111365770000_ltag012-B78","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-018-0603-7","article-title":"Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2026102111365770000_ltag012-B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117788","article-title":"Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: novel molecular approaches and therapeutic challenges","volume":"182","author":"Rataj","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"2026102111365770000_ltag012-B80","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/cancers15112944","article-title":"CAR-T Cells immunotherapies for the treatment of acute myeloid leukemia-recent advances","volume":"15","author":"Zarychta","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026102111365770000_ltag012-B81","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3324\/haematol.2022.281456","article-title":"Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia","volume":"108","author":"Niswander","year":"2023","journal-title":"Haematologica"},{"key":"2026102111365770000_ltag012-B82","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood.2023021570","article-title":"A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-gamma-induced CD38 expression","volume":"143","author":"Murtadha","year":"2024","journal-title":"Blood"},{"key":"2026102111365770000_ltag012-B83","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.3390\/cancers16213627","article-title":"Membrane antigen targeting in acute myeloid leukemia using antibodies or CAR-T cells","volume":"16","author":"Testa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026102111365770000_ltag012-B84","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1182\/bloodadvances.2022007059","article-title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","volume":"7","author":"Glisovic-Aplenc","year":"2023","journal-title":"Blood Adv"},{"key":"2026102111365770000_ltag012-B85","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026102111365770000_ltag012-B86","first-page":"5559","article-title":"CAR-NK cells for acute myeloid leukemia immunotherapy: past, present and future","volume":"13","author":"Zhang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"2026102111365770000_ltag012-B87","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.19746\/j.cnki.issn.1009-2137.2023.06.048","article-title":"[Research progress of chimeric antigen receptor modified NK cells in the treatment of acute myeloid leukemia --review]","volume":"31","author":"Peng","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2026102111365770000_ltag012-B88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed\/refractory AML: preclinical evaluation and phase I trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"2026102111365770000_ltag012-B89","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13045-022-01376-3","article-title":"Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia","volume":"15","author":"Caruso","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2026102111365770000_ltag012-B90","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells","volume":"23","author":"Du","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026102111365770000_ltag012-B91","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jcyt.2022.07.008","article-title":"Concurrent transposon engineering and CRISPR\/cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells","volume":"24","author":"Gurney","year":"2022","journal-title":"Cytotherapy"},{"key":"2026102111365770000_ltag012-B92","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3324\/haematol.2020.271908","article-title":"CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide","volume":"107","author":"Gurney","year":"2022","journal-title":"Haematologica"},{"key":"2026102111365770000_ltag012-B93","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1182\/bloodadvances.2022007405","article-title":"Off-the-shelf CAR-engineered natural killer cells targeting FLT3 enhance killing of acute myeloid leukemia","volume":"7","author":"Mansour","year":"2023","journal-title":"Blood Adv"},{"key":"2026102111365770000_ltag012-B94","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"2026102111365770000_ltag012-B95","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.stem.2024.05.006","article-title":"CAR macrophages tuning the immune symphony of anti-cancer therapies","volume":"31","author":"Paasch","year":"2024","journal-title":"Cell Stem Cell"},{"key":"2026102111365770000_ltag012-B96","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"2026102111365770000_ltag012-B97","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-025-00608-9","article-title":"CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells","volume":"14","author":"Guoyun","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"2026102111365770000_ltag012-B98","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int"},{"key":"2026102111365770000_ltag012-B99","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12935-018-0720-y","article-title":"T cell receptor-engineered T cells for leukemia immunotherapy","volume":"19","author":"Zhang","year":"2019","journal-title":"Cancer Cell Int"},{"key":"2026102111365770000_ltag012-B100","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1038\/s41467-025-60394-0","article-title":"A phase I\/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence","volume":"16","author":"Mazziotta","year":"2025","journal-title":"Nat Commun"},{"key":"2026102111365770000_ltag012-B101","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","article-title":"T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors","volume":"14","author":"Tsimberidou","year":"2021","journal-title":"J Hematol Oncol"},{"key":"2026102111365770000_ltag012-B102","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molimm.2012.03.023","article-title":"Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor","volume":"51","author":"Prosser","year":"2012","journal-title":"Mol Immunol"},{"key":"2026102111365770000_ltag012-B103","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"key":"2026102111365770000_ltag012-B104","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1172\/JCI97482","article-title":"Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia","volume":"129","author":"van der Lee","year":"2019","journal-title":"J Clin Invest"}],"container-title":["Immunotherapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/advance-article-pdf\/doi\/10.1093\/immadv\/ltag012\/68717222\/ltag012.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/6\/1\/ltag012\/68717222\/ltag012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article-pdf\/6\/1\/ltag012\/68717222\/ltag012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:37:07Z","timestamp":1792597027000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltag012\/8728101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":104,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"URL":"https:\/\/doi.org\/10.1093\/immadv\/ltag012","relation":{},"ISSN":["2732-4303"],"issn-type":[{"value":"2732-4303","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2025,12,31]]},"article-number":"ltag012"}}